Since their discovery in 2006, induced pluripotent stem cells have been poised to reprogram regenerative medicine. Twelve years on, here’s how far they’ve come.

The study will examine the efficacy of four drugs—an antiviral and three monoclonal antibodies—that are already being used to treat patients in Democratic Republic of Congo.

Precisely timed electrical stimulation and intensive rehabilitation restore some capacity to walk among three men more than four years after their debilitating injuries.

A trial to test whether so-called c-kit cardiac stem cells, first reported by Piero Anversa, could help patients with chronic heart failure has been halted in light of suspicion surrounding his work.

As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.

A new study suggests that sponsors downplay their influence when reporting trials carried out in collaboration with academic researchers.

Physician Peter Gøtzsche, a board member of the organization, has been an outspoken critic of certain vaccines and of the pharma industry in general.

Pharma companies are more compliant in posting results compared to universities.

Experiments in mice and people find that probiotic supplements don’t consistently change the composition of the gut microbiome, and may have adverse effects after antibiotics.